Intravitreally Administered Soluble VEGF Receptor-1 Variant Tested as a Potential Gene Therapeutic for Diabetic Retinopathy

Figure 1

Characteristics of rAAV2-sVEGFRv-1. In vitro characterization was performed using HUVECs, which showed via real-time PCR () (a) and ELISA () (b) that rAAV2-sVEGFRV-1 treatment led to significant increases in the mRNA and expression levels of the soluble VEGF receptor-1 variant, respectively, compared to mock-infected control cells and those infected with a virus vector expressing GFP. A tube formation assay showed (c) that the therapeutic virus vector markedly reduced (d) the formation of tube-like structures preceding VEGF-driven neovascularization (). and .

(a)

(b)

(c)

(d)